---
title: "Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292416910.md"
description: "Jefferies analyst Faisal Khurshid upgraded BeiGene to Buy with a $380 price target, citing strong Brukinsa revenue potential and pipeline progress. RBC Capital also maintained a Buy rating with a $451 target. Analysts highlight robust Q2 expectations, reduced competitive risks, and attractive entry points amid abating macro headwinds."
datetime: "2026-07-13T00:25:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292416910.md)
  - [en](https://longbridge.com/en/news/292416910.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292416910.md)
generator: "portal-rs"
---

# Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress

In a report released yesterday, Faisal Khurshid from Jefferies upgraded BeOne Medicines to a Buy, with a price target of $380.00.

Faisal Khurshid has given his Buy rating due to a combination of factors, primarily the conviction that Brukinsa can deliver revenue meaningfully ahead of current market expectations over both the near and long term. He now anticipates a strong second quarter with potential beat-and-raise dynamics, sustained by multi‑year treatment duration and expanding first‑line use in mantle cell lymphoma, while also seeing reduced risk from competing CLL therapies such as AV and Jaypirca.

In addition, he highlights that early‑stage solid tumor assets like CDK4, GPC3, and B7‑H4 have advanced into late‑stage development on encouraging data, warranting explicit valuation in his model. Khurshid also notes that forthcoming launches like Beqalzi (sonrotoclax) and the BTK CDAC, though not yet major revenue drivers, should enhance investor perception of the CLL franchise, and he believes the stock’s prior weakness tied to China biotech sentiment and macro headwinds offers an attractive entry point as those pressures gradually abate.

In another report released on July 7, RBC Capital also maintained a Buy rating on the stock with a $451.00 price target.

### Related Stocks

- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [BeOne Medicines and partners renew Brukinsa access programme for CLL](https://longbridge.com/en/news/296331290.md)
- [BeOne Medicines publishes Q2 clinical trials portfolio presentation detailing pipeline and study updates](https://longbridge.com/en/news/294973584.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)
- [Lowe’s Earns Buy Rating as Strong Earnings and Cash Generation Offset Lower-End Guidance](https://longbridge.com/en/news/296383656.md)
- [Baidu Analysts Slash Their Forecasts After Weak Q2 Results](https://longbridge.com/en/news/296374968.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**